Abstract 3541
Background
Cancer follow-up care continues to evolve to incorporate complex programs of supportive care to address long-term disease consequences. However, care may be prescriptive and fragmented, contributing to uncertainty among cancer survivors. As major stakeholders in follow-up care for cancer survivors, nurses are ideally positioned to ensure supportive care is person-centred and responsive to patients’ needs. We recently conducted a study to summarize the evidence related to cancer survivors’ preferences for supportive care and examine the ways in which these preferences are embedded in current guidelines and policies informing cancer survivorship care. This presentation discusses specific implications of these findings for oncology nursing.
Methods
Phase 1 of the study comprises an integrative review of the empirical literature regarding cancer survivors’ preferences for supportive care, with literature sourced from bibilographic databases and analysed according to principles of thematic analysis. In Phase 2, clinical practice guidelines and policy documents guiding supportive care in cancer survivorship are evaluated using content analysis methods to ascertain alignment with the findings of Phase 1. Finally, we conduct a critical analysis of the results through the lens of oncology nursing practice.
Results
Findings of the integrative review and content analysis of practice and policy guidelines highlight issues related to where and when supportive care is accessed and the types and features of supportive care services. Given that these gaps intersect with nursing practice, they serve as potential targets of knowledge translation activities. Impacts on survivors’ experiences are illustrated with exemplars derived from recent qualitative studies conducted in Canadian and Irish contexts.
Conclusions
As novel programs are developed to meet the needs of the growing population of cancer survivors, a consideration of survivors’ preferences is essential. We offer specific ways in which nursing practice and scholarship can be leveraged to ensure the translation of this knowledge into care, making visible the survivors’ voice in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract